Complexes Formed via Bioconjugation of Genetically Modified TMV Particles with Conserved Influenza Antigen: Synthesis and Characterization

[1]  P. Ivanov,et al.  Chimeric particles of tobacco mosaic virus as a platform for the development of next-generation nanovaccines , 2016, Nanotechnologies in Russia.

[2]  F. Krammer.  Novel universal influenza virus vaccine approaches. , 2016, Current opinion in virology.

[3]  R. Webby,et al.  A Single Dose TMV-HA Vaccine Protects Mice from H5N1 Influenza Challenge , 2016 .

[4]  A. McCormick,et al.  Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System , 2015, PloS one.

[5]  N. Ravin,et al.  Protection against Multiple Influenza A Virus Strains Induced by Candidate Recombinant Vaccine Based on Heterologous M2e Peptides Linked to Flagellin , 2015, PloS one.

[6]  W. Fiers,et al.  M2e-Based Universal Influenza A Vaccines , 2015, Vaccines.

[7]  Hualan Chen,et al.  Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens. , 2015, Virus research.

[8]  J. Atabekov,et al.  High-Level Systemic Expression of Conserved Influenza Epitope in Plants on the Surface of Rod-Shaped Chimeric Particles , 2014, Viruses.

[9]  R. Webby,et al.  Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge , 2014, Human vaccines & immunotherapeutics.

[10]  N. Steinmetz,et al.  Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. , 2014, Virology.

[11]  R. Narain.  Chemistry of bioconjugates : synthesis, characterization, and biomedical applications , 2014 .

[12]  O. Kiselev,et al.  Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. , 2013, Current pharmaceutical design.

[13]  Robert P. Friedland,et al.  Humans Have Antibodies against a Plant Virus: Evidence from Tobacco Mosaic Virus , 2013, PloS one.

[14]  A. Hill,et al.  Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus , 2013, Vaccine.

[15]  T. Tumpey,et al.  Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. , 2011, Vaccine.

[16]  Hamidreza Ghandehari,et al.  Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  Igor V. Petrunia,et al.  Trastuzumab-binding peptide display by Tobacco mosaic virus. , 2010, Virology.

[18]  Kathryn Chaloner,et al.  Identification, Characterization and Immunogenicity of an O-Antigen Capsular Polysaccharide of Francisella tularensis , 2010, PloS one.

[19]  W. Fiers,et al.  M2e-based universal influenza A vaccine. , 2009, Vaccine.

[20]  D. Rasko,et al.  Native Outer Membrane Proteins Protect Mice against Pulmonary Challenge with Virulent Type A Francisella tularensis , 2008, Infection and Immunity.

[21]  D. Discher,et al.  Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.

[22]  M. Norgard,et al.  Characterization of Francisella tularensis Outer Membrane Proteins , 2006, Journal of bacteriology.

[23]  K. Palmer,et al.  Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. , 2006, Bioconjugate chemistry.

[24]  A. Benko,et al.  Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. , 2006, Vaccine.

[25]  Zhengkai Xu,et al.  A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco. , 2006, Vaccine.

[26]  K. Palmer,et al.  Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. , 2006, Virology.

[27]  Michael T Harris,et al.  Improved metal cluster deposition on a genetically engineered tobacco mosaic virus template , 2005, Nanotechnology.

[28]  M. Buchmeier,et al.  Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. V. Regenmortel,et al.  The antigenicity of tobacco mosaic virus. , 1999 .

[30]  M. Hein,et al.  Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. , 1995, Vaccine.

[31]  B. Moss,et al.  Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes , 1987, The Journal of experimental medicine.

[32]  J. Oxford,et al.  Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells , 1977, Nature.